Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

NCT03385395 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped IND has been closed.

Conditions

Alpha 1-Antitrypsin Deficiency

Interventions

DRUG: OctaAlpha1
DRUG: Glassia

Sponsor

Octapharma